Wuhan Healthgen Biotechnology (SHSE:688765) ROC %: -5.86% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688765 Wuhan Healthgen Biotechnology Corp SHSE:688765
19 GF Score
Price ¥51.25
! 7 Warning Signs
View Full Analysis

What is Wuhan Healthgen Biotechnology ROC %?

Wuhan Healthgen Biotechnology SHSE:688765 -6.82% 19 ROC % is -5.86% as of Mar. 2026. GuruFocus rates SHSE:688765 with a GF Score™ of 19/100. The stock has 7 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Wuhan Healthgen Biotechnology's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -5.86%.

As of today (2026-07-17), Wuhan Healthgen Biotechnology's WACC % is 10.34%. Wuhan Healthgen Biotechnology's ROC % is -8.28% (calculated using TTM income statement data). Wuhan Healthgen Biotechnology earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Wuhan Healthgen Biotechnology  (SHSE:688765) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Wuhan Healthgen Biotechnology's WACC % is 10.34%. Wuhan Healthgen Biotechnology's ROC % is -8.28% (calculated using TTM income statement data). Wuhan Healthgen Biotechnology earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Wuhan Healthgen Biotechnology ROC % Related Terms

Wuhan Healthgen Biotechnology ROC % Historical Data

* Premium members only.

The historical data trend for Wuhan Healthgen Biotechnology's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Healthgen Biotechnology ROC % Chart

Wuhan Healthgen Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -64.38 -32.22 -28.76 -19.26 -8.96

Wuhan Healthgen Biotechnology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Dec19 Dec20 Dec21 Jun22 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.92 -12.08 -13.00 -7.42 -5.86
SHSE:688765
19GF Score
Wuhan Healthgen Biotechnology Corp SHSE:688765
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuhan Healthgen Biotechnology ROC % Calculation

Wuhan Healthgen Biotechnology's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-156.035 * ( 1 - 0% )/( (846.771 + 2637.61)/ 2 )
=-156.035/1742.1905
=-8.96 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1061.812 - 210.366 - ( 160.402 - max(0, 232.667 - 237.342+160.402))
=846.771

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3702.888 - 395.837 - ( 669.441 - max(0, 453.597 - 2162.103+669.441))
=2637.61

Wuhan Healthgen Biotechnology's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-160.14 * ( 1 - 0% )/( (2637.61 + 2824.002)/ 2 )
=-160.14/2730.806
=-5.86 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3702.888 - 395.837 - ( 669.441 - max(0, 453.597 - 2162.103+669.441))
=2637.61

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3641.232 - 418.506 - ( 398.724 - max(0, 566.414 - 1877.813+398.724))
=2824.002

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -5.86% mean?
Wuhan Healthgen Biotechnology (SHSE:688765) has a ROC % of -5.86% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Wuhan Healthgen Biotechnology and its competitors.
Is Wuhan Healthgen Biotechnology's ROC % too high?
Wuhan Healthgen Biotechnology's current ROC % is -5.86%. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's ROC % compare to ZTS and UTHR?
Wuhan Healthgen Biotechnology's ROC % of -5.86% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.46, based on 990 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Wuhan Healthgen Biotechnology and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan Healthgen Biotechnology's current ROC % is -5.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current ROC % of -5.86%. The current ROC % is -5.86%. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current ROC % is -5.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan Healthgen Biotechnology Business Description

Address No. 268, Shendun 5th Road, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430206
Wuhan Healthgen Biotechnology Corp is engaged in Research, development, production and commercialization of plant-based molecular medicines.
19GF Score

Get the complete analysis for SHSE:688765

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥51.25
Price